100 related articles for article (PubMed ID: 10669329)
1. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines.
Boyer JD; Cohen AD; Vogt S; Schumann K; Nath B; Ahn L; Lacy K; Bagarazzi ML; Higgins TJ; Baine Y; Ciccarelli RB; Ginsberg RS; MacGregor RR; Weiner DB
J Infect Dis; 2000 Feb; 181(2):476-83. PubMed ID: 10669329
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
Cao H; Kaleebu P; Hom D; Flores J; Agrawal D; Jones N; Serwanga J; Okello M; Walker C; Sheppard H; El-Habib R; Klein M; Mbidde E; Mugyenyi P; Walker B; Ellner J; Mugerwa R;
J Infect Dis; 2003 Mar; 187(6):887-95. PubMed ID: 12660934
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 DNA based vaccine induces a CD8 mediated cross-clade CTL response.
Boyer JD; Chattergoon M; Shah A; Ginsberg R; MacGregor RR; Weiner DB
Dev Biol Stand; 1998; 95():147-53. PubMed ID: 9855425
[TBL] [Abstract][Full Text] [Related]
4. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
5. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
6. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
AIDS Vaccine Evaluation Group 022 Protocol Team
J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial.
Boyer JD; Chattergoon MA; Ugen KE; Shah A; Bennett M; Cohen A; Nyland S; Lacy KE; Bagarazzi ML; Higgins TJ; Baine Y; Ciccarelli RB; Ginsberg RS; MacGregor RR; Weiner DB
Clin Immunol; 1999 Jan; 90(1):100-7. PubMed ID: 9884357
[TBL] [Abstract][Full Text] [Related]
8. High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.
Goepfert PA; Horton H; McElrath MJ; Gurunathan S; Ferrari G; Tomaras GD; Montefiori DC; Allen M; Chiu YL; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Keefer MC; Baden LR; Corey L;
J Infect Dis; 2005 Oct; 192(7):1249-59. PubMed ID: 16136469
[TBL] [Abstract][Full Text] [Related]
9. Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA.
Moss RB; Diveley J; Jensen FC; Gouveia E; Carlo DJ
J Hum Virol; 2001; 4(1):39-43. PubMed ID: 11213932
[TBL] [Abstract][Full Text] [Related]
10. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
[TBL] [Abstract][Full Text] [Related]
11. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data.
MacGregor RR; Boyer JD; Ciccarelli RB; Ginsberg RS; Weiner DB
J Infect Dis; 2000 Jan; 181(1):406. PubMed ID: 10608800
[No Abstract] [Full Text] [Related]
12. Helminth infection suppresses T-cell immune response to HIV-DNA-based vaccine in mice.
Da'Dara AA; Lautsch N; Dudek T; Novitsky V; Lee TH; Essex M; Harn DA
Vaccine; 2006 Jun; 24(24):5211-9. PubMed ID: 16675073
[TBL] [Abstract][Full Text] [Related]
13. Identification of HIV-1 specific T lymphocyte responses in highly exposed persistently seronegative Chinese.
Liu HW; Hong KX; Ma J; Yuan L; Liu S; Chen JP; Zhang YZ; Ruan YH; Xu JQ; Shao YM
Chin Med J (Engl); 2006 Oct; 119(19):1616-21. PubMed ID: 17042974
[TBL] [Abstract][Full Text] [Related]
14. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein.
Deml L; Bojak A; Steck S; Graf M; Wild J; Schirmbeck R; Wolf H; Wagner R
J Virol; 2001 Nov; 75(22):10991-1001. PubMed ID: 11602739
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
[TBL] [Abstract][Full Text] [Related]
16. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1.
Kelleher AD; Puls RL; Bebbington M; Boyle D; Ffrench R; Kent SJ; Kippax S; Purcell DF; Thomson S; Wand H; Cooper DA; Emery S
AIDS; 2006 Jan; 20(2):294-7. PubMed ID: 16511428
[TBL] [Abstract][Full Text] [Related]
17. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
18. Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting.
Li W; Li S; Hu Y; Tang B; Cui L; He W
Vaccine; 2008 Jun; 26(26):3282-90. PubMed ID: 18472194
[TBL] [Abstract][Full Text] [Related]
19. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
Huang XG; Xu JQ; Ren L; Qiu C; Zhang N; Liu LX; Wan YM; Peng H; Shao YM
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3109-13. PubMed ID: 17313761
[TBL] [Abstract][Full Text] [Related]
20. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]